Fanconi Anemia

H8713; Phase I/II Study of Allogeneic Stem Cell Transplantation for Patients with Hematologic Malignancy, Using Haploidentical Family Donors and Sub-Myeloablative Conditioning with Campath 1H: This study uses a monoclonal antibody, low dose chemotherapy and radiation in combination with haploidentical allogeneic stem cell transplantation to treat patients with hematologic malignancies who have already received a stem cell transplant or who also have other complications such as kidney, liver, or heart disease.
Optional:  Participants in this study may participate in the following protocol: 

H9938; CD45 (Yth-24 And Yth-54) and CD52 (Campath-1h) Monoclonal Antibody Conditioning Regimen for HLA-Identical Donor Stem Cell Transplantation of Patients with Fanconi Anemia: This study uses monoclonal antibodies in combination with a matched allogeneic stem cell transplantation to treat patients with Fanconi Anemia.
Optional:  Participants in this study may participate in the following protocol: 
H-11428; A Phase I Trial Evaluating the Use of RFT5-dgA to Deplete Alloreactive Cells for Patients with Fanconi Anemia after Haploidentical Stem Cell Transplantation:  This study is an add on study in which patients who have received a haploidentical stem cell transplant on protocol H-9938 are eligible to receive allodepleted T cells following engraftment.

©2002, Cell And Gene Therapy, Baylor College of Medicine
One Baylor Plaza, N1002, Houston, TX 77030, (713)798-1246
URL: http://www.bcm.edu/genetherapy Email:cagt@bcm.edu
(Modified: September 21st, 2007 - jb)